September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
5 citations
,
April 2019 in “Dermatologic therapy” This case report described a 67-year-old man with moderate psoriasis who developed persistent generalized hypertrichosis after 4 months of treatment with secukinumab.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.